(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2006 (20.04.2006)

PCT

(10) International Publication Number
WO 2006/040334 A1

(51) International Patent Classification:
A61K 39/015 (2006.01)

(21) International Application Number:
PCT/EP2005/055209

(22) International Filing Date: 13 October 2005 (13.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/619,056	14 October 2004 (14.10.2004)	US
04105035.2	14 October 2004 (14.10.2004)	EP

(71) Applicants *(for all designated States except US)*: **CRUCELL HOLLAND B.V.** [NL/NL]; Archimedesweg 4, NL-2333 CN Leiden (NL). **GLAXOSMITHKLINE BIOLOGICALS, S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). **WALTER REED ARMY INSTITUTE OF RESEARCH** [US/US]; 503 Robert Grant Avenue, Silver Spring, Maryland 20910-7500 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PAU, Maria Grazia** [IT/NL]; Bargelaan 80, NL-2333 CW Leiden (NL). **GOUDSMIT, Jaap** [NL/NL]; Koninginneweg 4, NL-1075 CX Amsterdam (NL). **COHEN, Joseph, D.** [US/BE]; GlaxoSmithKline, Rue de l'Institut 89, B-1330 Rixensart (BE). **DUBOIS, Patrice, M.** [BE/BE]; GlaxoSmithKline, Rue de l'Institut 89, B-1330 Rixensart (BE). **STEWART, V. Ann** [US/US]; 503 Robert Grant Avenue, Silver Spring, Maryland 20910-7500 (US). **HEPPNER, Donald** [US/US]; 503 Robert Grant Avenue, Silver Spring, Maryland 20910-7500 (US).

(74) Agents: **KLEIN, Bart** et al.; Crucell Holland B.V., c/o Archimedesweg 4, NL-2333 CN Leiden (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MALARIA PRIME/BOOST VACCINES

(57) Abstract: The invention relates to novel vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.

WO 2006/040334 A1